Pharmaceutical company Eli Lilly announced a $2 billion expansion in Indiana during a press conference at the Governor’s Mansion on Wednesday.

Indianapolis-based pharmaceutical giant Eli Lilly last week said it was shifting its business focus in Russia, but all 167 employees there remain employed.

The Food and Drug Administration said it cleared the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of COVID-19.

A virtual pilot program recently provided students in seven Indianapolis area middle schools the opportunity to experience dozens of jobs in the STEM fields.

Congress is debating a Democratic proposal, H.R.3, that would allow the federal government to negotiate prescription drug prices in an effort to lower costs.

Pharmaceutical giant Eli Lilly is partnering with patient advocacy group Susan G. Komen to expand resources to support Black women facing breast cancer in Indianapolis, Chicago and St. Louis. The spokeswoman for the new partnership is an Olympic athlete who has battled breast cancer.

The new price -- starting Jan. 1 -- will be about $80 per vial and comparable to how much a vial of Lilly's brand name Humalog insulin cost in 2008.

Starting Jan. 1, Lilly will drop the cost of its Insulin Lispro Injection -- the generic of its insulin Humalog -- by 40 percent, saving about $50 per vial.

An additional $5 million will go towards improving health equity through the Diabetes Impact Project, or DIP IN.

The announcement comes a few weeks after the Food and Drug Administration approved a treatment from rival Biogen despite warnings from the agency's independent advisers that it hasn't been shown to help slow the brain-destroying disease.